A case of serotonin syndrome caused by venlafaxine and lithium.
Serotonin syndrome occurred under treatment with average dose of Venlafaxine and lithium in a 50 year-old female patient with a history of sensitiveness to SSRIs. Plasma levels of Venlafaxine and its metabolite were within reference range. Parmacogenetic evaluation indicated normal metabolic pathway.
Mekler
G
G
Psychiatric University Hospital, Zurich, Switzerland.
Woggon
B
B
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D018692:Antimanic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D003511:Cyclohexanols / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000009:adverse effects*; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013577:Syndrome; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D003511:Cyclohexanols; D018020:Lithium Compounds; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride